| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 02/02/2006 | WO2002094990A3 Receptors and membrane-associated proteins |
| 02/02/2006 | US20060026720 Plant proteins |
| 02/02/2006 | US20060026700 Tissue specific genes and gene clusters |
| 02/02/2006 | US20060026698 Transgenic transchromosomal rodents for making human antibodies |
| 02/02/2006 | US20060026696 Humanized immunoglobulin loci |
| 02/02/2006 | US20060026695 Transgenically produced fusion proteins |
| 02/02/2006 | US20060025576 Multivalent antibodies and uses therefor |
| 02/02/2006 | US20060025575 Hybridoma cell line producing monoclonal antibodies to bind to, to detect and qualitatively and quantitatively measure the presence of epitopes of prion proteins; neurodegenerative diseases of the central nervous system |
| 02/02/2006 | US20060025574 32 human secreted proteins |
| 02/02/2006 | US20060025573 Reducing the immunogenicity of fusion proteins |
| 02/02/2006 | US20060025572 Mammalian cell surface antigens; related reagents |
| 02/02/2006 | US20060025565 purified polypeptide and fusion protein for promoting the survival, growth, proliferation, or maintenance of neurons in an injured but not severed spinal cord; axonal regeneration, side effect reduction of scar tissue formation |
| 02/02/2006 | US20060025362 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation |
| 02/02/2006 | US20060025339 Corticotropin releasing factor 2 receptor agonists |
| 02/02/2006 | US20060025338 Compositions and methods for treatment of lymphatic and venous vessel arterialization |
| 02/02/2006 | US20060025334 Vanilloid receptor-2 ligands for treating anxiety or depression |
| 02/02/2006 | US20060024807 Kinase nucleic acids and polypeptides encoded by these nucleic acids; kinase inhibiitor design and indentifying inhibitors |
| 02/02/2006 | US20060024804 Isoforms isolated and purified from mammalian colostrum |
| 02/02/2006 | US20060024800 Method of modulating the activity of functional immune molecules |
| 02/02/2006 | US20060024798 Gene knockout; gene overexpression; liposomes |
| 02/02/2006 | US20060024795 Interferon-Like molecules and uses thereof |
| 02/02/2006 | US20060024792 G-protein coupled receptors |
| 02/02/2006 | US20060024782 Production of a monoclonal antibody in a heterokaryon filamentous fungus or in a filamentous fungal host cell |
| 02/02/2006 | US20060024772 Parathyroid hormone antibodies and related methods |
| 02/02/2006 | US20060024766 Bifunctional molecules |
| 02/02/2006 | US20060024761 Protein biopolymer markers predictive of alzheimer's disease |
| 02/02/2006 | US20060024760 Human brain carboxypeptidase B |
| 02/02/2006 | US20060024759 Complex of a chaperone with beta-amyloid and methods employing this complex |
| 02/02/2006 | US20060024754 Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 02/02/2006 | US20060024750 identification of the natural ligand for the orphan G-Protein Coupled Receptor; diagnosis of conditions involving dysregulated receptor activity |
| 02/02/2006 | US20060024748 Cytoxan antibodies and immunoassay |
| 02/02/2006 | US20060024729 Mechanosensitive mammalian potassium channels activatable by polyunsaturated fatty acids and the use of said channels in drug screening |
| 02/02/2006 | US20060024708 Porcine sulfotransferase 2A1 polynucleotide sequence, protein, and methods of use for same |
| 02/02/2006 | US20060024700 determining whether a hepatitis C virus-infected human has an increased risk for developing liver fibrosis, comprising testing nucleic acid from the human for a polymorphism in gene TLR4 as represented by position 101 of SEQ ID NO: 18973 or its complement |
| 02/02/2006 | US20060024688 Alterations of fibulin genes in macular degeneration |
| 02/02/2006 | US20060024683 Transcription factor of MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances |
| 02/02/2006 | US20060024670 Influenza virus vaccine composition and methods of use |
| 02/02/2006 | US20060024668 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
| 02/02/2006 | US20060024666 Humanized antibodies against the venezuelan equine encephalitis virus |
| 02/02/2006 | US20060024379 Protein microspheres having injectable properties at high concentrations |
| 02/02/2006 | US20060024317 Chemical linkers and conjugates thereof |
| 02/02/2006 | US20060024316 Prostatic cancer vaccine |
| 02/02/2006 | US20060024315 Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| 02/02/2006 | US20060024313 Agents that disrupt dimer formation in DPP-IV family of prolyl dipeptidases |
| 02/02/2006 | US20060024311 Administering anti-TK1 antibody conjugated to cytotoxic agent consisting of pokeweed antiviral protein (PAP), ricin, abrin, gelonin, saporin, and alpha-sarcin; detecting and diagnosing viral infections |
| 02/02/2006 | US20060024310 Methods of treating TNFalpha-mediated tissue injury using anti-TNF antibodies and peptides |
| 02/02/2006 | US20060024308 High affinity anti-TNF-alpha antibodies and method |
| 02/02/2006 | US20060024307 For treatment and prevention of acute and chronic infectious diseases, mostly of viral etiology, and for producing an immunomodulating effect; comprising a homeopathically potentised form of monoclonal, polyclonal, or natural antibody to gamma interferon, does not suppress the activity of the interferon |
| 02/02/2006 | US20060024306 Methods of treating and preventing colitis involving il-13 and nk-t cells |
| 02/02/2006 | US20060024305 Camp-regulated phosphoprotein for diagnostic and therapeutic use in neurodegenerative diseases |
| 02/02/2006 | US20060024302 Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same |
| 02/02/2006 | US20060024301 Prostate-specific polypeptides and fusion polypeptides thereof |
| 02/02/2006 | US20060024300 Immunoglobulin variants and uses thereof |
| 02/02/2006 | US20060024299 Human osteoclast derived cathepsin |
| 02/02/2006 | US20060024298 Optimized Fc variants |
| 02/02/2006 | US20060024297 Tie complex binding proteins |
| 02/02/2006 | US20060024296 As an antagonist that inhibits immunoglobulin secretion; autoimmune disorders; antiproliferative , anticarcinogenic and antiarthritic agents; inflammatory bowel disease |
| 02/02/2006 | US20060024295 Method for treating lupus |
| 02/02/2006 | US20060024294 Compositions for prevention and treatment of infections caused by parasites in animals |
| 02/02/2006 | US20060024293 Antibody for use in the treatment and prevention of sepsis, infections, autoimmune and graft-versus-host diseases; biodegradable, biocompatible polymer and human antibody, or an antigen-binding portion thereof, that dissociates from human TNF alpha |
| 02/02/2006 | US20060024292 Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform |
| 02/02/2006 | US20060024291 Protocadherin materials and methods |
| 02/02/2006 | US20060024267 TNFr/OPG-like molecules and uses thereof |
| 02/02/2006 | CA2574828A1 Crystallization of antibodies or fragments thereof |
| 02/02/2006 | CA2574654A1 Compositions and methods of use for mgd-csf in disease treatment |
| 02/02/2006 | CA2574432A1 Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same |
| 02/02/2006 | CA2573359A1 Method of treating sjogren's syndrome |
| 02/02/2006 | CA2571445A1 Markers for brain damage |
| 02/02/2006 | CA2570610A1 Method and device for detecting feline immunodeficiency virus |
| 02/01/2006 | EP1621637A1 ppGalNac-T6 mRNA or peptide as a new marker for the detection of cancer cells |
| 02/01/2006 | EP1621627A2 Use of porcine gala (1,3) galactosyl transferase in xenograft therapies |
| 02/01/2006 | EP1621623A2 BASB029 polynucleotide(s) and polypeptides from Neisseria meningitis |
| 02/01/2006 | EP1621622A1 Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof |
| 02/01/2006 | EP1621621A1 Human 7tm protein receptors and polynucleotides encoding the same |
| 02/01/2006 | EP1621620A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/01/2006 | EP1621619A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/01/2006 | EP1621616A1 Human antihuman interleukin-18 antibody, fragment thereof and method of using the same |
| 02/01/2006 | EP1621555A1 Immunogen, composition for immunological use, and method of producing antibody using the same |
| 02/01/2006 | EP1621554A1 Immunoglobulins devoid of light chains |
| 02/01/2006 | EP1621553A1 Antibodies that inhibit transport activity of peptide transporters |
| 02/01/2006 | EP1621548A2 Polypeptides, CDNAs encoding the same and utilization thereof |
| 02/01/2006 | EP1621547A1 C of malarial pre-erythrocytic stage polypeptide molecules and lipids |
| 02/01/2006 | EP1621546A1 Peptide ligands specific to immonoglobulins |
| 02/01/2006 | EP1621209A2 Vaccines based on domains of chimeric immunoglobulin E peptides |
| 02/01/2006 | EP1621206A1 Chimeric cytokines and uses thereof |
| 02/01/2006 | EP1620726A2 Polypeptides related to natriuretic peptides and methods of their identification and use |
| 02/01/2006 | EP1620549A1 Process for the production of biological substances by perfusion culturing of suspended animal cells |
| 02/01/2006 | EP1620467A2 Optimized fc variants and methods for their generation |
| 02/01/2006 | EP1620463A2 Compositions and methods comprising a ligand of chemerin receptor |
| 02/01/2006 | EP1620457A2 Inducers of recombinant protein expression |
| 02/01/2006 | EP1620127A2 Methods for treating taxol-induced gut disorder |
| 02/01/2006 | EP1620072A1 Zinc-containing sustained-release composition, its preparation, and method for producing the same |
| 02/01/2006 | EP1619992A2 Expressed genes that define the osteoclast phenotype |
| 02/01/2006 | EP1547613A4 Medication and method for treating pathological syndrome |
| 02/01/2006 | EP1530580A4 Humanized gm-csf antibodies |
| 02/01/2006 | EP1483415A4 A non-invasive diagnostic test utilizing histone modification markers |
| 02/01/2006 | EP1466622A4 Medicinal agent and method for curing diseases accompanied with vascular dystonia |
| 02/01/2006 | EP1200479B1 Multiple cytokine-antibody complexes |
| 02/01/2006 | EP1196566B1 Expression vectors and methods |
| 02/01/2006 | EP1179592B1 Proteins nectin-3 |